Johnson E, Berge V, Høgåsen K
Research Forum, Ullevål Hospital, Oslo, Norway.
Scand J Immunol. 1994 Mar;39(3):281-5. doi: 10.1111/j.1365-3083.1994.tb03372.x.
Vitronectin occupies the metastable binding site of C5b-7, which is unable to insert membranes as part of the complement lytic attack. Some evidence has been presented that vitronectin inhibits also membrane-associated pore formation by inhibiting C9 polymerization in the terminal complement complex (TCC). The authors wished to add to this background by studying the effect of vitronectin on formation of TCC on a carbohydrate surface like agarose beads, an alternative complement pathway activator. Bound TCC was detected by monoclonal and polyclonal antibodies to C9-neoepitopes. Soluble SC5b-7 and TCC (SC5b-9) did not bind to the agarose beads. Using serum or isolated complement factors for the alternative and terminal pathways, the authors found that vitronectin reduced the density of C9-neoepitopes on the beads. As there was no convincing evidence for association of vitronectin with the factors C5b-8 of the agarose-bound TCC, it was concluded that vitronectin bound directly to C9 in TCC and inhibited C9 polymerization within the complex. The authors have shown that TCC can bind to a carbohydrate surface like agarose (an alternating polymer of galactose moieties) in the absence of lipid. These results suggest that vitronectin can limit the lytic effect of membrane-bound TCC by inhibiting C9 polymerization.
玻连蛋白占据C5b - 7的亚稳结合位点,该位点无法作为补体溶细胞攻击的一部分插入细胞膜。已有一些证据表明,玻连蛋白还通过抑制末端补体复合物(TCC)中的C9聚合来抑制膜相关孔的形成。作者希望通过研究玻连蛋白对在碳水化合物表面(如琼脂糖珠,一种替代补体途径激活剂)上TCC形成的影响来补充这一背景知识。通过针对C9新表位的单克隆和多克隆抗体检测结合的TCC。可溶性SC5b - 7和TCC(SC5b - 9)不与琼脂糖珠结合。使用替代途径和末端途径的血清或分离的补体因子,作者发现玻连蛋白降低了珠子上C9新表位的密度。由于没有令人信服的证据表明玻连蛋白与琼脂糖结合的TCC的C5b - 8因子相关联,因此得出结论,玻连蛋白直接与TCC中的C9结合并抑制复合物内的C9聚合。作者已经表明,在没有脂质的情况下,TCC可以与碳水化合物表面(如琼脂糖,半乳糖部分的交替聚合物)结合。这些结果表明,玻连蛋白可以通过抑制C9聚合来限制膜结合TCC的溶细胞作用。